Question 1

Am I eligible for this trial based on my previous treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation clinical trial (NCT04685135). Contact the study team or your healthcare provider for specific answers.

Question 2

How does MRTX849 compare to docetaxel in terms of side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation clinical trial (NCT04685135). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation clinical trial (NCT04685135). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation clinical trial (NCT04685135). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer progresses while I'm in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation clinical trial (NCT04685135). Contact the study team or your healthcare provider for specific answers.

Question 6

Will my insurance cover the costs associated with this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation clinical trial (NCT04685135). Contact the study team or your healthcare provider for specific answers.

What this study is about